Is PD-1 blockade a potential therapy for HBV?
作者信息
Féray Cyrille, López-Labrador F Xavier
机构信息
Centre Hépatobiliaire, Paul Brousse Hospital, Inserm-Paris Sud Research Unit 1193, University Paris Sud, Villejuif, Paris, France.
Virology Laboratory Genomics and Health Area FISABIO - Public Health, Generalitat Valenciana, Valencia, Spain.
出版信息
JHEP Rep. 2019 Aug 28;1(3):142-144. doi: 10.1016/j.jhepr.2019.07.007. eCollection 2019 Sep.
Abstract
摘要
相似文献
1
Is PD-1 blockade a potential therapy for HBV?程序性死亡受体1（PD-1）阻断疗法是治疗乙型肝炎病毒（HBV）的潜在疗法吗？
JHEP Rep. 2019 Aug 28;1(3):142-144. doi: 10.1016/j.jhepr.2019.07.007. eCollection 2019 Sep.
2
HBeAg seroconversion is associated with a more effective PD-L1 blockade during chronic hepatitis B infection.在慢性乙型肝炎感染期间，HBeAg血清学转换与更有效的程序性死亡受体配体1（PD-L1）阻断相关。
JHEP Rep. 2019 Jun 28;1(3):170-178. doi: 10.1016/j.jhepr.2019.06.001. eCollection 2019 Sep.
3
Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation.PD-1 阻断在非活动携带者患者中恢复 HBV 特异性 CD8+ T 细胞功能与 T 细胞分化有关。
J Hepatol. 2014 Dec;61(6):1212-9. doi: 10.1016/j.jhep.2014.07.005. Epub 2014 Jul 10.
4
Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.抗 PD-1/PD-L1 阻断免疫疗法治疗乙型肝炎病毒感染相关的晚期肝细胞癌：文献综述。
Front Immunol. 2020 May 28;11:1037. doi: 10.3389/fimmu.2020.01037. eCollection 2020.
5
OX40 stimulation and PD-L1 blockade synergistically augment HBV-specific CD4 T cells in patients with HBeAg-negative infection.OX40 刺激和 PD-L1 阻断协同增强 HBeAg 阴性感染患者的 HBV 特异性 CD4 T 细胞。
J Hepatol. 2019 Jun;70(6):1103-1113. doi: 10.1016/j.jhep.2019.02.016. Epub 2019 Feb 28.
6
Augmentation of hepatitis B virus-specific cellular immunity with programmed death receptor-1/programmed death receptor-L1 blockade in hepatitis B virus and HIV/hepatitis B virus coinfected patients treated with adefovir.在接受阿德福韦治疗的乙型肝炎病毒（HBV）感染者及HIV/HBV合并感染者中，通过程序性死亡受体-1/程序性死亡受体配体-1阻断增强HBV特异性细胞免疫。
AIDS Res Hum Retroviruses. 2013 Apr;29(4):665-72. doi: 10.1089/AID.2012.0320. Epub 2013 Feb 11.
7
Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma.阻断Tim-3或/和PD-1可逆转HBV相关肝细胞癌中肿瘤浸润淋巴细胞的功能障碍。
Bull Cancer. 2018 May;105(5):493-501. doi: 10.1016/j.bulcan.2018.01.018. Epub 2018 Mar 22.
8
Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B.抗病毒的肝内 T 细胞应答可通过阻断慢性乙型肝炎中的程序性死亡-1 通路来恢复。
Gastroenterology. 2010 Feb;138(2):682-93, 693.e1-4. doi: 10.1053/j.gastro.2009.09.052. Epub 2009 Sep 30.
9
PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients.程序性死亡受体1（PD-1）上调与慢性乙型肝炎患者的乙肝病毒特异性T细胞功能障碍有关。
Mol Immunol. 2008 Feb;45(4):963-70. doi: 10.1016/j.molimm.2007.07.038. Epub 2007 Sep 14.
10
Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T cells against HBV, but not HCV.联合阻断程序性死亡受体 1 和激活 CD137 可增强人肝 T 细胞对 HBV 的反应，但对 HCV 无作用。
Gastroenterology. 2012 Dec;143(6):1576-1585.e4. doi: 10.1053/j.gastro.2012.08.041. Epub 2012 Aug 25.
引用本文的文献
1
Negative Immune Checkpoint Inhibitors.阴性免疫检查点抑制剂
Pharmaceutics. 2025 May 28;17(6):713. doi: 10.3390/pharmaceutics17060713.
2
Functional Cure for Hepatitis B Virus: Challenges and Achievements.乙肝病毒的功能性治愈：挑战与成就
Int J Mol Sci. 2025 Apr 11;26(8):3633. doi: 10.3390/ijms26083633.
3
Stem-like CD8+ T cells preserve HBV-specific responses in HBV/HIV co-infection.干细胞样CD8 + T细胞在HBV/HIV合并感染中保留HBV特异性反应。
medRxiv. 2025 Apr 3:2025.03.30.25324898. doi: 10.1101/2025.03.30.25324898.
4
Clearance of Hepatitis C Virus following Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma: Case Report.肝细胞癌免疫检查点抑制剂治疗后丙型肝炎病毒清除：病例报告
Case Rep Gastroenterol. 2024 Jun 27;18(1):347-351. doi: 10.1159/000539646. eCollection 2024 Jan-Dec.
5
Advances in discovery of novel investigational agents for functional cure of chronic hepatitis B: A comprehensive review of phases II and III therapeutic agents.慢性乙型肝炎功能性治愈新型研究药物的发现进展：II期和III期治疗药物的全面综述
World J Hepatol. 2024 Mar 27;16(3):331-343. doi: 10.4254/wjh.v16.i3.331.
6
Sequential Therapy with Ropeginterferon Alfa-2b and Anti-Programmed Cell Death 1 Antibody for Inhibiting the Recurrence of Hepatitis B-Related Hepatocellular Carcinoma: From Animal Modeling to Phase I Clinical Results.罗氏干扰素 α-2b 和抗程序性细胞死亡蛋白 1 抗体序贯治疗抑制乙型肝炎相关肝细胞癌复发：从动物模型到 I 期临床结果。
Int J Mol Sci. 2023 Dec 28;25(1):433. doi: 10.3390/ijms25010433.
7
Dynamics of Hepatitis B Virus Covalently Closed Circular DNA: A Mini-Review.乙型肝炎病毒共价闭合环状DNA的动态变化：一篇综述。
Microorganisms. 2023 Feb 27;11(3):600. doi: 10.3390/microorganisms11030600.
8
Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis.新型聚乙二醇干扰素治疗慢性病毒性肝炎。
Viruses. 2022 May 25;14(6):1128. doi: 10.3390/v14061128.
9
HBV/HIV Coinfection: Impact on the Development and Clinical Treatment of Liver Diseases.乙肝病毒/艾滋病毒合并感染：对肝脏疾病发展及临床治疗的影响
Front Med (Lausanne). 2021 Oct 4;8:713981. doi: 10.3389/fmed.2021.713981. eCollection 2021.
10
Persistence of Hepatitis B Virus Infection: A Multi-Faceted Player for Hepatocarcinogenesis.乙型肝炎病毒感染的持续存在：肝癌发生的多面参与者
Front Microbiol. 2021 Aug 30;12:678537. doi: 10.3389/fmicb.2021.678537. eCollection 2021.
本文引用的文献
1
Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study.尼伏单抗联合或不联合治疗性疫苗治疗病毒抑制慢性乙型肝炎的抗 PD-1 阻断：一项初步研究。
J Hepatol. 2019 Nov;71(5):900-907. doi: 10.1016/j.jhep.2019.06.028. Epub 2019 Jul 12.
2
HBV Immune-Therapy: From Molecular Mechanisms to Clinical Applications.HBV 免疫治疗：从分子机制到临床应用。
Int J Mol Sci. 2019 Jun 5;20(11):2754. doi: 10.3390/ijms20112754.
3
Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis.纳武利尤单抗治疗晚期肝细胞癌：索拉非尼经治亚洲人群队列分析。
J Hepatol. 2019 Sep;71(3):543-552. doi: 10.1016/j.jhep.2019.05.014. Epub 2019 Jun 7.
4
Is the function of the HBeAg really unknown?HBeAg 的功能真的未知吗？
Hum Vaccin Immunother. 2019;15(9):2187-2191. doi: 10.1080/21645515.2019.1607132. Epub 2019 May 9.
5
A global scientific strategy to cure hepatitis B.全球治愈乙型肝炎的科学策略。
Lancet Gastroenterol Hepatol. 2019 Jul;4(7):545-558. doi: 10.1016/S2468-1253(19)30119-0. Epub 2019 Apr 10.
6
Breakdown of adaptive immunotolerance induces hepatocellular carcinoma in HBsAg-tg mice.适应性免疫耐受的崩溃导致 HBsAg-tg 小鼠发生肝细胞癌。
Nat Commun. 2019 Jan 15;10(1):221. doi: 10.1038/s41467-018-08096-8.
7
Success of immune checkpoint blockade therapies - mechanisms and implications for hepatology.免疫检查点阻断疗法的成功——机制及其对肝病学的意义
Z Gastroenterol. 2019 Jan;57(1):74-86. doi: 10.1055/a-0805-6936. Epub 2019 Jan 14.
8
Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.免疫检查点抑制剂相关神经毒性的诊断和治疗：病例举例与文献复习。
Oncologist. 2019 Apr;24(4):435-443. doi: 10.1634/theoncologist.2018-0359. Epub 2018 Nov 27.
9
Immune checkpoint inhibitors and cardiovascular toxicity.免疫检查点抑制剂与心血管毒性。
Lancet Oncol. 2018 Sep;19(9):e447-e458. doi: 10.1016/S1470-2045(18)30457-1.
10
PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection.PD-1 阻断部分恢复慢性乙型肝炎感染中功能失调的病毒特异性 B 细胞。
J Clin Invest. 2018 Oct 1;128(10):4573-4587. doi: 10.1172/JCI121957. Epub 2018 Aug 7.
Zotero 插件